Keywords : diagnostic, Diagnostics, Immunology
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the ...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,000 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of companion diagnostic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of companion diagnostics partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by companion diagnostics partnering company A-Z , deal type definitions and companion diagnostics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostic partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostic technologies and products.
Report scope
Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.
Companion Diagnostics Partnering Terms and Agreements includes:
o Trends in companion diagnostics dealmaking in the biopharma industry since 2007
o Analysis of companion diagnostics deal structure
o Access to headline, upfront, milestone and royalty data
o Case studies of real-life companion diagnostics deals
o Access to over 1,000 companion diagnostics contract documents
o The leading companion diagnostics deals by value since 2007
o Most active companion diagnostics dealmakers since 2007
o The leading companion diagnostics partnering resources
In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:
o Company A-Z o Headline value
o Stage of development at signing
o Deal component type
o Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 companion diagnostics deals.
Analyzing actual contract agreements allows assessment of the following:
o What are the precise companion diagnostics rights granted or optioned?
o What is actually granted by the agreement to the partner company?
o What exclusivity is granted?
o What is the payment structure for the deal?
o How are sales and payments audited?
o What is the deal term?
o How are the key terms of the agreement defined?
o How are IPRs handled and owned?
o Who is responsible for commercialization?
o Who is responsible for development, supply, and manufacture?
o What happens when there is a change of ownership?
o What sublicensing and subcontracting provisions have been agreed?
o Which boilerplate clauses does the company insist upon?
o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
o Which jurisdiction does the company insist upon for agreement law?
Number of pages: The report is comprised of 335 pages.
Companion Diagnostics Partnering Terms and Agreements provides the reader with the following key benefits:
In-depth understanding of companion diagnostics deal trends since 2007
Analysis of the structure of companion diagnostics agreements with numerous real life case studies
Comprehensive access to over 1,000 actual companion diagnostics deals entered into by the world’s biopharma companies
Detailed access to actual companion diagnostics deals and contracts enter into by the leading fifty bigpharma companies
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Diagnostics Industry
Table of Contents
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in companion diagnostic dealmaking
2.1. Introduction
2.2. Companion diagnostic partnering over the years
2.3. Bigpharma companion diagnostic dealmaking activity
2.4. Most active companion diagnostics dealmakers
2.5. Companion diagnostic partnering by deal type
2.6. Companion diagnostic partnering by disease type
2.7 Average deal terms for companion diagnostics
2.7.1 Companion diagnostic headline values
2.7.2 Companion diagnostic upfront payments
2.7.3 Companion diagnostic milestone payments
2.7.4 Companion diagnostics royalty rates
Chapter 3 – Leading companion diagnostic deals
3.1. Introduction
3.2. Top companion diagnostic deals by value
3.3. Top companion diagnostic deals involving bigpharma
Chapter 4 – Bigpharma companion diagnostic deals
4.1. Introduction
4.2. How to use bigpharma companion diagnostic partnering deals
4.3. Bigpharma companion diagnostic partnering company profiles
Abbott
Amgen
Astellas
AstraZeneca
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Merck & Co
Merck KGaA
Novartis
Pfizer
Roche
Sanofi
Servier
Takeda
UCB
Chapter 5 – Companion diagnostic dealmaking directory
5.1. Introduction
5.2. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
Regulatory
5.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Development
Distribution
Equity purchase
Evaluation
Grant
Licensing
Manufacturing
Marketing
Option
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
5.4. By therapy area
Breast
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Genitourinary
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Pediatrics
Psychiatry
Public health
Respiratory
Sexual Health
Chapter 6 – Companion diagnostics dealmaking by technology type
6.1. Introduction
Companion Diagnostics
Chapter 7 – Companion diagnostics partnering resource center
7.1. Online companion diagnostics partnering
7.2. Companion diagnostic partnering events
7.3. Further reading on companion diagnostic dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Therapy Reports
List of figures
Figure 1: Companion diagnostic partnering since 2007
Figure 2: Bigpharma – top 50 – companion diagnostic deals 2007 to 2013
Figure 3: Bigpharma companion diagnostic deal frequency – 2007 to 2013
Figure 4: Active companion diagnostics dealmaking activity– 2007 to 2013
Figure 5: Companion diagnostic partnering by deal type since 2007
Figure 6: Companion diagnostic partnering by disease type since 2007
Figure 7: Companion diagnostic partnering by oncology target since 2007
Figure 8: Companion diagnostic deals with a headline value
Figure 9: Companion diagnostic deal headline value distribution, US$million -Disovery
Figure 10: Companion diagnostic deal headline value distribution, US$million -Preclinical
Figure 11: Companion diagnostic deal headline value distribution, US$million -Marketed
Figure 11: Summary median headline value by stage of development, 2007-2013
Figure 13: Companion diagnostic deals with upfront payment values
Figure 14: Companion diagnostic deal upfront value distribution, US$million – 2007-2013 – Discovery
Figure 15: Companion diagnostic deal upfront value distribution, US$million – 2007-2013 – Preclinical
Figure 16: Summary median headline value by stage of development, 2007-2013
Figure 17: Companion diagnostic deals with milestone payments values
Figure 18: Companion diagnostic deal milestone value distribution, US$million – 2007-2013 – Discovery
Figure 19: Companion diagnostic deal milestone value distribution, US$million – 2007-2013 –
Figure 20: Companion diagnostic deal milestone value distribution, US$million – 2007-2013 –
Figure 21: Companion diagnostic deals with royalty rates values
Figure 22: Companion diagnostic deal royalty rates value distribution, US$million – 2007-2013 – Phase III
Figure 23: Summary median headline value by stage of development, 2007-2013
Figure 24: Top companion diagnostic deals by value since 2007
Figure 23: Top companion diagnostic deals signed by bigpharma value since 2007
Figure 26: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Cardiovascular)
Figure 27: Recent deals (Jan 2007 to Feb 2013) - By therapy area (CNS)
Figure 28: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Dermatology)
Figure 29: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Gastrointestinal)
Figure 30: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Genetic disorders)
Figure 31: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Genitourinary)
Figure 32: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Gynaecology)
Figure 33: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Immunology)
Figure 34: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Infectives)
Figure 35: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Metabolic)
Figure 36: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Musculoskeletal)
Figure 37: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Oncology)
Figure 38: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Pediatrics)
Figure 39: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Psychiatry)
Figure 40: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Public health)
Figure 41: Recent deals (Jan 2007 to Feb 2013) - By therapy area (Respiratory)
Figure 42: Recent deals (Jan 2007 to Feb 2013) - By therapy area (sexual health)
Figure 43: Online partnering resources
Figure 44: Forthcoming partnering events
